Skip to main content
TipRanks
Go Ultimate75% OFF

DaVita (TRL) AI Stock Analysis

1 Followers
CH:TRL

DaVita

(BX Swiss:TRL)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Steady growth and cash generationDaVita combines steady revenue expansion with substantial operating and free cash flow, showing that its core dialysis model remains highly cash generative. This supports ongoing investment in care capabilities, technology and growth initiatives while providing internally generated funding for the business.
Negative Factors
High leverage and negative equityThe combination of substantial debt and negative shareholders’ equity materially reduces financial flexibility. It leaves DaVita more sensitive to operating shocks, limits room for discretionary capital allocation and increases the importance of sustaining cash generation while managing obligations.

DaVita Business Overview & Revenue Model

Company Description

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, suppleme...

DaVita Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|Next Earnings Date:Feb 11, 2027
Earnings Call SentimentPositive

The call was predominantly positive, with solid third-quarter results, improved clinical outcomes, strong expanded HD adoption and rollout readiness, significant IKC earnings growth, continued international improvement and maintained full-year free cash flow expectations. These positives were tempered by higher technology spending, below-historical treatment volume growth, missed-treatment pressure, commercial-mix and ACA headwinds, higher operating costs and uncertainty around future ESRD reimbursement adjustments and policy economics.

Positive Updates

Improved Fluid Management and Patient Outcomes
Specialized clinical protocols, teammate education and proprietary digital tools produced a 10% improvement in treatments achieving optimal fluid removal, a 5% improvement in patients' management of weight gain between treatments and nearly a 5-pound reduction in average patient weight. Management said these advancements are supporting continued mortality improvement and better daily quality of life.

Negative Updates

Higher-than-Expected U.S. Dialysis Technology Spending
Technology investment in U.S. dialysis was higher than forecasted heading into 2026 and represented a drag on full-year financial performance. Technology spend increased more than 20% year-over-year in the third quarter, although management expects the rate of growth to decelerate rather than decline in 2027.

Company Guidance

For full year 2026, DaVita now expects adjusted operating income within a range of $2.175 billion to $2.25 billion, adjusted earnings per share within a range of $14.30 to $15.20, free cash flow between $1 billion and $1.25 billion, IKC adjusted operating income of at least $65 million, and approximately $135 million of international adjusted operating income; the company expects a $40 million year-over-year headwind from ACA exchanges, an approximately 1% headwind to fourth-quarter treatment volume from year-over-year day mix, and treatments per normalized day up more than 1% in Q4, while 2027 volume growth is expected to be higher than volume growth in 2026, pharmaceutical costs are expected to come down, and IT spend is expected to decelerate from 20-plus percent growth but continue to grow. Expanded HD is expected to have no material net impact on adjusted operating income for 2026 or 2027, with the positive impact of lower mortality and higher volume growth beginning in the back half of 2028 and supporting a path back to 2% or greater volume growth by 2029. For full year '27, the estimated net impact of the ESRD final rule is 1.5% to 2%, with 1% worth about $30 million a year, while the 40 basis points excluding TDAPA is fixed for the year and the 3.1% TDAPA component applies only to Q1 and is expected to come down significantly in Q2 and stay down and potentially further decline over the course of the year.

DaVita Risk Analysis

DaVita disclosed 26 risk factors in its most recent earnings report. DaVita reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

DaVita Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CH:TRL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
THCTHC87Outperform$22.76B8.2460.60%―6.23%136.09%
ENSGENSG75Outperform$10.99B27.2716.63%0.14%17.49%19.82%
EHCEHC70Outperform$13.83B21.7625.17%0.55%9.36%20.78%
FMSFMS66Neutral$11.75B13.416.34%3.92%4.27%26.14%
HCAHCA64Neutral$104.25B16.49-100.45%0.61%5.82%16.59%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%FMSHCAEHCTHCENSGDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:TRL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FMSFresenius Medical Care22.03-0.36-1.63%
HCAHca Healthcare499.0525.195.32%
EHCEncompass Health140.9929.8126.82%
THCTenet Healthcare Corp.286.0393.6348.66%
ENSGThe Ensign188.4111.116.27%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.